Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease.
|Title||Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease.|
|Publication Type||Journal Article|
|Year of Publication||2012|
|Authors||DuBois, Rebecca M., P Slavish Jake, Baughman Brandi M., Yun Mi-Kyung, Bao Ju, Webby Richard J., Webb Thomas R., and White Stephen W.|
|Keywords||Animals, Cell Line, Chick Embryo, Chickens, Crystallography, X-Ray, Dogs, Drug Design, Endoribonucleases, Enzyme Inhibitors, Humans, Influenza A Virus, H5N1 Subtype, Influenza in Birds, Molecular Docking Simulation, Protein Structure, Tertiary, RNA Replicase, Structure-Activity Relationship, Viral Proteins|
Emerging influenza viruses are a serious threat to human health because of their pandemic potential. A promising target for the development of novel anti-influenza therapeutics is the PA protein, whose endonuclease activity is essential for viral replication. Translation of viral mRNAs by the host ribosome requires mRNA capping for recognition and binding, and the necessary mRNA caps are cleaved or "snatched" from host pre-mRNAs by the PA endonuclease. The structure-based development of inhibitors that target PA endonuclease is now possible with the recent crystal structure of the PA catalytic domain. In this study, we sought to understand the molecular mechanism of inhibition by several compounds that are known or predicted to block endonuclease-dependent polymerase activity. Using an in vitro endonuclease activity assay, we show that these compounds block the enzymatic activity of the isolated PA endonuclease domain. Using X-ray crystallography, we show how these inhibitors coordinate the two-metal endonuclease active site and engage the active site residues. Two structures also reveal an induced-fit mode of inhibitor binding. The structures allow a molecular understanding of the structure-activity relationship of several known influenza inhibitors and the mechanism of drug resistance by a PA mutation. Taken together, our data reveal new strategies for structure-based design and optimization of PA endonuclease inhibitors.
|Alternate Journal||PLoS Pathog.|
|PubMed Central ID||PMC3410894|
|Grant List||AI098757 / AI / NIAID NIH HHS / United States |
CA21765 / CA / NCI NIH HHS / United States
R01 AI098757 / AI / NIAID NIH HHS / United States